Comparative Pharmacology
Head-to-head clinical analysis: AMCILL versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCILL versus POLYCILLIN PRB.
AMCILL vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic